Compliance
Selling GLP-1 peptides (semaglutide, tirzepatide) legally
GLP-1 and GLP-1-adjacent peptides carry unusually high regulatory risk. Here is the hardline policy a bankable business needs — and what the FDA has said about compounding them.
Peptide Merchant Services — Compliance
Selling GLP-1 peptides (semaglutide, tirzepatide) legally
GLP-1 and GLP-1-adjacent peptides carry unusually high regulatory risk. Here is the hardline policy a bankable business needs — and what the FDA has said about compounding them.
Updated June 10, 2026 · 7 min read · https://peptidemerchantadvocates.com/resources/glp-1-peptide-compliance
The short answer
GLP-1 and GLP-1-adjacent peptides (semaglutide, tirzepatide, liraglutide, retatrutide, cagrilintide, mazdutide) are the highest-risk category. For a bankable business they should be FDA-approved commercial product, or handled only through a tightly controlled pharmacy/compounding model with product-specific legal opinions. No compounded retatrutide or cagrilintide, no "generic Ozempic/Wegovy/Mounjaro," and no claims of FDA approval or equivalence.
Why are GLP-1 peptides treated as a special case?
GLP-1s are the most scrutinized peptides in the market, with active FDA attention and enormous consumer demand that pulls businesses toward non-compliant shortcuts. The risk is not just regulatory — it is the kind that ends merchant accounts and draws warning letters.
What the FDA has said about compounding GLP-1s
FDA says retatrutide and cagrilintide cannot be used in compounding under federal law. It says semaglutide sodium and semaglutide acetate are different active ingredients from those in the approved drugs, and that it is not aware of a lawful basis for their use in compounding.
FDA has also proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound those drugs from bulk substances.
The hardline product policy
For a defensible business, the prohibited list is explicit:
- No compounded retatrutide or cagrilintide.
- No semaglutide sodium or semaglutide acetate.
- No "generic Ozempic," "generic Wegovy," "generic Mounjaro," or "generic Zepbound."
- No "same active ingredient" claim unless approved by regulatory counsel.
- No compounded copies of commercially available FDA-approved drugs unless a narrow, documented exception applies.
- No claim that compounded GLP-1s are FDA-approved, generic, clinically proven, or equivalent to the branded drug.
What a bankable GLP-1 model looks like
Practically, GLP-1s should be either FDA-approved commercial product moving through licensed channels, or handled only through a tightly controlled pharmacy/compounding model backed by product-specific legal opinions. If you cannot point to one of those for a given GLP-1 SKU, it does not belong in the catalog.
Key takeaways
- GLP-1 and GLP-1-adjacent peptides are the highest-risk category.
- FDA says retatrutide and cagrilintide cannot be used in compounding; it sees no lawful basis for semaglutide sodium/acetate.
- FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list.
- Never claim a compounded GLP-1 is FDA-approved, generic, or equivalent to the branded drug.
Frequently asked questions
Can you legally sell compounded semaglutide or tirzepatide?
Only inside a tightly controlled, lawful pharmacy/compounding model with product-specific legal review — and FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The bankable default is FDA-approved commercial product through licensed channels.
Can retatrutide or cagrilintide be compounded?
No. FDA has said retatrutide and cagrilintide cannot be used in compounding under federal law.
Is "generic Ozempic" or "generic Mounjaro" allowed?
No. Marketing a compounded product as a "generic" of a branded GLP-1, or claiming it is FDA-approved or equivalent, is prohibited in a defensible model.
Is semaglutide sodium the same as the approved drug?
No. FDA says semaglutide sodium and semaglutide acetate are different active ingredients from those in the approved drugs, and it is not aware of a lawful basis for their use in compounding.
Related compliance resources
More guidance on staying compliant and keeping payment processing in place.
- 10 things to know when selling BPC-157BPC-157 is one of the most searched peptides and one of the hardest to sell lawfully. Ten things every seller should understand about its regulatory status, marketing limits, and payment acceptance. 9 min read
- How to not get your peptide merchant account shut downA step-by-step operating playbook to keep a peptide merchant account boarded: what triggers a shutdown, the controls that prevent it, and the warning signs that mean you have days, not months. 10 min read
- How to legally run a peptide company in 2026A plain-English operating model for a defensible peptide business: lawful product pathways, the right entity, restricted marketing, and an examiner-ready payments file. 9 min read
- Is it legal to sell peptides? The four lawful pathwaysSelling peptides is legal only inside one of four FDA pathways. Here is what each one (FDA-approved, 503B, 503A, and research/IND) requires — and what falls outside the law. 8 min read
- 503A vs 503B for peptides: which compounding pathway fits?The difference between 503A and 503B decides whether you can sell office stock, who can be the seller, and what you can compound. Here is the practical breakdown for peptides. 7 min read
- Why "research use only" peptides can't be sold for human useSelling RUO or "not for human consumption" peptides into the physician-to-patient channel is one of the highest-risk models in the industry. Here is why — and what the FDA has said. 6 min read
This article is general educational information about regulatory frameworks (FDA, FTC, 503A/503B, DSCSA), not legal advice. Peptide compliance turns on product-specific and state-specific facts — review your model with qualified FDA, healthcare, and payments counsel before acting.
Keep reading
9 min read
How to legally run a peptide company in 2026
A plain-English operating model for a defensible peptide business: lawful product pathways, the right entity, restricted marketing, and an examiner-ready payments file.
8 min read
Is it legal to sell peptides? The four lawful pathways
Selling peptides is legal only inside one of four FDA pathways. Here is what each one (FDA-approved, 503B, 503A, and research/IND) requires — and what falls outside the law.
7 min read
503A vs 503B for peptides: which compounding pathway fits?
The difference between 503A and 503B decides whether you can sell office stock, who can be the seller, and what you can compound. Here is the practical breakdown for peptides.
Get a free statement review — no obligation.
We review your processing statement and flag every risk indicator underwriters will ask about. Back to you within 24 hours.